Analysts See $-0.12 EPS for Ionis Pharmaceuticals, Inc. (IONS)

October 13, 2018 - By olga

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Logo

Analysts expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to report $-0.12 EPS on November, 6.After having $-0.05 EPS previously, Ionis Pharmaceuticals, Inc.’s analysts see 140.00 % EPS growth. The stock increased 3.76% or $1.63 during the last trading session, reaching $45. About 849,664 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has declined 20.61% since October 14, 2017 and is downtrending. It has underperformed by 36.23% the S&P500.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company has market cap of $6.18 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet. It currently has negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: which released: “Key events next week – healthcare” on September 28, 2018, also with their article: “Roche’s risdiplam shows positive action in SMA studies” published on October 03, 2018, published: “Biogen’s Spinraza shows positive effect in presymptomatic infants with SMA” on October 08, 2018. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: and their article: “Akcea (AKCA), Ionis (IONS) Receive FDA Approval of TEGSEDI (Earlier)” published on October 07, 2018 as well as‘s news article titled: “Meet Ionis Pharma’s Newest Collaboration” with publication date: October 10, 2018.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News